Ibritumomab Tiuxetan

ATC — · 3 markets · 3 records

Ibritumomab Tiuxetan 3 markets · 3 records Forms

GB 1 records · 1 strengths

3.2 mg/2 mLkitZevalin 3.2mg/2ml kit for radiopharmaceutical preparation

HK 1 records · 1 strengths

Records without a stated strength · 1 ZEVALIN FOR INFUSION 1.6MG/ML

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Zevalin

Side-by-side table

Strength / form / release	GB	HK	EU
3.2 mg/2 mL kit	Zevalin 3.2mg/2ml kit for radiopharmaceutical preparation	not recorded	not recorded
not disclosed unknown	not recorded	ZEVALIN FOR INFUSION 1.6MG/ML	Zevalin

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.